I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more
I-Mab (IMAB) - Total Assets
Latest total assets as of September 2025: $277.41 Million USD
Based on the latest financial reports, I-Mab (IMAB) holds total assets worth $277.41 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
I-Mab - Total Assets Trend (2017–2024)
This chart illustrates how I-Mab’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
I-Mab - Asset Composition Analysis
Current Asset Composition (December 2024)
I-Mab's total assets of $277.41 Million consist of 83.1% current assets and 16.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.1% |
| Accounts Receivable | $1.17 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how I-Mab's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: I-Mab's current assets represent 83.1% of total assets in 2024, an increase from 67.5% in 2017.
- Cash Position: Cash and equivalents constituted 32.1% of total assets in 2024, up from 30.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 29.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
I-Mab Competitors by Total Assets
Key competitors of I-Mab based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
I-Mab - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - I-Mab generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - I-Mab is currently not profitable relative to its asset base.
I-Mab - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.47 | 15.99 | 9.28 |
| Quick Ratio | 14.47 | 15.99 | 9.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $216.68 Million | $ 176.44 Million | $ 4.77 Billion |
I-Mab - Advanced Valuation Insights
This section examines the relationship between I-Mab's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.76 |
| Latest Market Cap to Assets Ratio | 1.82 |
| Asset Growth Rate (YoY) | -91.9% |
| Total Assets | $212.68 Million |
| Market Capitalization | $387.37 Million USD |
Valuation Analysis
Above Book Valuation: The market values I-Mab's assets above their book value (1.82 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: I-Mab's assets decreased by 91.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for I-Mab (2017–2024)
The table below shows the annual total assets of I-Mab from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $212.68 Million | -91.86% |
| 2023-12-31 | $2.61 Billion | -35.86% |
| 2022-12-31 | $4.07 Billion | -27.64% |
| 2021-12-31 | $5.63 Billion | -11.12% |
| 2020-12-31 | $6.33 Billion | +264.52% |
| 2019-12-31 | $1.74 Billion | -26.87% |
| 2018-12-31 | $2.38 Billion | +131.72% |
| 2017-12-31 | $1.03 Billion | -- |